Signaturefd LLC Buys 346 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Signaturefd LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 13.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,894 shares of the medical research company’s stock after acquiring an additional 346 shares during the quarter. Signaturefd LLC’s holdings in IQVIA were worth $569,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GSA Capital Partners LLP acquired a new position in shares of IQVIA during the third quarter worth about $230,000. Empowered Funds LLC boosted its position in IQVIA by 33.9% during the 3rd quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock worth $814,000 after acquiring an additional 871 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of IQVIA by 20.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 43,177 shares of the medical research company’s stock worth $10,231,000 after acquiring an additional 7,369 shares in the last quarter. Pathstone Holdings LLC lifted its position in shares of IQVIA by 4.8% in the third quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company’s stock worth $3,434,000 after purchasing an additional 667 shares in the last quarter. Finally, Caprock Group LLC boosted its holdings in IQVIA by 11.7% during the third quarter. Caprock Group LLC now owns 3,003 shares of the medical research company’s stock worth $712,000 after purchasing an additional 315 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on IQV shares. Barclays cut their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. UBS Group dropped their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Stephens started coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Price Performance

NYSE:IQV opened at $186.80 on Thursday. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $256.29. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm’s 50-day simple moving average is $195.71 and its 200 day simple moving average is $209.36. The firm has a market cap of $32.93 billion, a price-to-earnings ratio of 24.91, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.